Italia markets closed

Prime Medicine, Inc. (PRME)

NasdaqGM - NasdaqGM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
7,11-0,79 (-10,00%)
Alla chiusura: 04:00PM EDT
7,10 -0,01 (-0,14%)
Dopo ore: 07:29PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente7,90
Aperto7,80
Denaro7,07 x 100
Domanda7,15 x 200
Min-Max giorno7,07 - 7,92
Intervallo di 52 settimane4,11 - 15,75
Volume656.069
Media Volume827.071
Capitalizzazione853,42M
Beta (mensile su 5 anni)N/D
Rapporto PE (ttm)N/D
EPS (ttm)-2,18
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A14,10
  • GlobeNewswire

    Prime Medicine to Present at Upcoming Investor Conferences

    Cambridge, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present at three upcoming investor conferences: BMO Biopharma Virtual Spotlight Series: Latest Advances in Genome / Epigenome Editing: Fireside chat on Tuesday, September 26, 2023, at 10

  • GlobeNewswire

    Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates

    -- Presented new preclinical data demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting ability of PASSIGE™ platform to multiplex edit CAR-T cells at ASGCT Annual Meeting -- -- Entered strategic collaboration with Cimeio Therapeutics; multiplexing Cimeio’s shielded variants with therapeutic edits may meaningfully expand reach of Prime Editing -- -- Cash, cash equivalents, investments and restricted cash balance of $221.1 million as of June 30, 2023 -- CAMBR

  • GlobeNewswire

    Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome

    -- Collaboration combines Prime Medicine’s Prime Editing platform with Cimeio Therapeutics’ Shielded Cell and Immunotherapy Pairs™ (SCIP™) platform -- -- Aim to reduce toxicity of conditioning regimens and introduce new therapeutic options that can expand the utility of hematopoietic stem cell (HSC) transplant and in vivo genetic therapies -- CAMBRIDGE, Mass. and BASEL, Switzerland, June 22, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delive